The U.S. is showing signs of targeting China's domestic surveillance and the tech supporting it.Technologyread more
Pro-EU parties are set to hold onto two-thirds of the seats at the EU Parliament.Europe Politicsread more
The projected result comes shortly after Conservative Party leader Theresa May announced her resignation as prime minister on Friday morning.Europe Politicsread more
A Beijing decision to rapidly and sharply cut its excessive and unsustainable trade surplus with the U.S. would change for the better the bilateral relationship, writes...World Economyread more
Former Apple CEO John Sculley says this skill is vital to all great business leadership.Successread more
Prime Minister Narendra Modi has to make sure that India becomes a highly competitive manufacturing hub where global investors will look to invest, the chairman of India...Asia Economyread more
The U.S. and Japan will likely reach a trade settlement in the next six to nine months that will "give each side something to claim credit for," says Glen Fukushima, former...World Economyread more
Bitcoin surged more than 9% from the day before to hit its highest level in more than a year.Technologyread more
Stocks in Asia were mixed Monday morning as investors watched for developments from U.S. President Donald Trump's state visit to Japan as well as results from the European...Asia Marketsread more
Sources say the talks have picked up speed in recent days and could lead to an announcement regarding a merger or partnership by Monday.Autosread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Pfizer Chief Executive Officer Ian Read will hand over the reins of the largest U.S. drugmaker to veteran insider Albert Bourla in January, after eight years at the helm, in the backdrop of increased scrutiny over drug pricing.
Under Read, a Scot who joined the company in 1978, Pfizer has weathered patent expirations of several blockbusters, including cholesterol drug Lipitor, through dealmaking, expansion in emerging markets and cost cuts.
The company also won 30 approvals from the U.S. health regulator during his tenure. Read, however, failed to pull off two high-profile mega deals.
Pfizer walked away from buying British drugmaker AstraZeneca in 2014 as the deal met with opposition from both countries over jobs and corporate tax maneuvers.
A move to acquire Ireland-based Allergan in 2016 was scuttled after a decision by the Obama administration limited benefits of a tax inversion deal.
"Now is the right time for a leadership change and Albert is the right person to guide Pfizer through the coming era," Read, who will become executive chairman, said.
Shares of the drugmaker, which have risen about 160 percent since Read took over as CEO in December 2010, were trading up nearly a percent at $44.42.
Bourla, 56, was appointed chief operating officer at the start of this year and was widely seen as the leading candidate for the top job.
Before becoming COO, he led the drugmaker's Innovative Health business, which recorded revenue of $31.4 billion in 2017. Pfizer brought in $52.5 billion in overall revenue in 2017.
"This looks like a well-considered transition, thus I'm not convinced it will herald a major change in strategic thinking, particularly as Ian will still stay on as chairman," Berenberg analyst Alistair Campbell said.
The appointment comes at a time when the Trump administration has been pressuring drugmakers to lower prescription costs.
After a conversation between Read and President Trump, Pfizer in July decided to defer price increases for no more than six months.
The company, which has been trying to sell its consumer healthcare business for the past one year, is bracing for patent expiration of its neurological disease treatment Lyrica, which raked in $1.2 billion in second-quarter sales.
"The timing of this transition makes sense given Reed's age," Edward Jones analyst Ashtyn Evans said.
Last week, rival Merck said it would amend a policy to allow its head, Kenneth Frazier, to remain CEO beyond 2019 when he was expected to retire.